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Introduction, epidemiology, and etiology
Twenty thousand new primary central nervous system (CNS)
neoplasms are diagnosed each year in the United States. CNS
tumors are the second most frequent malignancy of childhood,
and their incidence in adults increases with advancing age.
Importantly, cancers of the CNS are among the most devastat-
ing of human malignancies, affecting the organ that defines the
“self,” often severely compromising quality of life (Louis et al.,
2000). There are dozens of different types of CNS neoplasms
recognized by the World Health Organization (WHO). Malignant
gliomas of the cerebral hemispheres in adults and medulloblas-
tomas of the cerebellum in children are the most common and
most studied of primary malignancies and are reviewed here.
Malignant gliomas are so named because tumor cells phe-
notypically resemble normal glia; nonetheless, the tumors may
arise from pleuripotential precursors. Malignant gliomas are
classified as astrocytomas, oligodendrogliomas, and oligoastro-
cytomas and are histologically graded as WHO II, III, or IV. The
most aggressive, grade IV, astrocytoma is referred to as
glioblastoma. Medulloblastomas, which are thought to arise by
malignant transformation of cerebellar granular cell progenitors,
have a poorly differentiated histologic appearance, are all WHO
grade IV and are staged according to the extent of disease.
Although the cause of most CNS neoplasms remains enig-
matic, certain associations are evident. Epidemiologic studies,
in both adults and children, have linked exposure to ionizing
radiation and the subsequent development of CNS tumors.
Gliomas and medulloblastomas also occur in rare families,
implicating a genetic etiology in some cases. Malignant gliomas
arise in association with neurofibromatosis type 1, as well as
with the Li-Fraumeni and Turcot syndromes. Medulloblastomas
occur in Turcot and Gorlin syndromes.
Conventional diagnostics and therapeutics
Adults with gliomas present with seizures, headaches, or focal
neurological deficits (DeAngelis, 2001). Neuroimaging with
magnetic resonance (MR) is essential for localization. Surgery
is required for sampling and is a component of therapy; howev-
er, because hemispheric gliomas always infiltrate the surround-
ing brain, surgical resection is seldom curative. Pathological
examination establishes tumor type and grade, with subsequent
therapy dependent on these parameters. Survival is determined
by many interrelated biological and therapeutic variables. In
general, younger age, oligodendroglial subtype, lower grade,
extensive resection, radiotherapy, and chemosensitivity predict
longer survival. Patients with these favorable prognostic factors
may live 20 years or more. In contrast, elderly patients with
unresectable grade IV astrocytic gliomas live about six months
despite radiotherapy, and such tumors are rarely chemosensi-
tive.This extreme heterogeneity suggests that malignant glioma
is many diseases, each with its own behavior and therapeutic
requirements. Over the years, many new therapies have been
tried, sometimes with much fanfare, but to date these have
failed. Current therapies—surgery, radiation, and chemothera-
py—are helpful and becoming safer, but the prospect that any
combination of contemporary treatments can be curative now
seems remote.
Children with medulloblastoma typically present with signs
and symptoms attributable to a posterior fossa mass, including
headache and vomiting from obstructive hydrocephalus, ataxia,
and cranial nerve deficits (Packer et al., 1999). MR scanning
reveals a cerebellar mass, with metastatic spread in about one-
third of cases. Because of the tendency to disseminate, therapy
consists of attempted surgical resection, external beam radia-
tion to the entire neuraxis with a boost to the tumor bed, and
multidrug chemotherapy for approximately one year.
Histological features do not reliably predict behavior, although
rare variants may follow more favorable or more aggressive
courses. Prognostic staging is based on age, extent of surgical
resection, and the presence of metastases. The overall 5-year
survival of good risk patients is approximately 80% and about
65% for poor risk. However, life-altering cognitive, growth, and
neuroendocrine deficits occur in the majority of survivors due in
large part to the aggressive therapy that is necessary for tumor
control. Consequently, as for malignant glioma, new therapeutic
approaches are required.
The genetic basis of glioma and medulloblastoma
tumorigenesis
Genetic analyses of gliomas in adults have demonstrated alter-
ations characteristic of specific tumor subtypes and grades
(Figure 1; Kleihues and Cavenee, 2000). The earliest known
changes in astrocytomas have involved inactivating mutations
of TP53 as well as overexpression of the platelet-derived growth
factor (PDGF) and PDGF receptor, and less commonly allelic
loss of chromosome 22q. The progression to grade III astrocy-
toma is associated with inactivation of the p16-cdk4-pRb path-
way as well as allelic loss of 19q. Further progression to grade
IV (i.e., glioblastoma) occurs with loss of chromosome 10,
sometimes with PTEN inactivation, and with amplification,
rearrangement, and overexpression of the epidermal growth
factor receptor (EGFR) gene. Oligodendroglial tumors common-
ly demonstrate allelic loss of 1p and 19q. As oligoden-
drogliomas become grade III lesions, they too undergo inactiva-
tion of the p16 pathway and may lose chromosome 10 and
amplify EGFR. Oligoastrocytomas have histological features of
both astrocytoma and oligodendroglioma, but are genotypically
unambiguous, harboring the molecular signature of either oligo-
dendroglioma or astrocytoma (Figure 1; Kleihues and Cavenee,
2000).
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The most common genetic alterations in medulloblastomas
are loss of 17p distal to TP53 and isochromosome 17q (Figure
2; Biegel, 1999; Kleihues and Cavenee, 2000). Insights into spe-
cific genetic pathways altered in these tumors have been pro-
vided by two inherited disorders: Gorlin syndrome, due to
germline mutation of the Shh receptor PTCH, and Turcot syn-
drome, caused by mutation of either APC or DNA mismatch
repair genes. About 10%–20% of sporadic tumors, typically of
the desmoplastic variant, have been found to have mutations of
genes in the Shh-PTCH-SMO pathway. Mutations related to
Wnt-β-catenin-APC have also been documented but are rare.
Molecular genetic assays have been clinically helpful in distin-
guishing medulloblastomas from the histologically similar but
clinically distinct atypical teratoid/rhabdoid tumors that have 22q
loss and INI1/SNF5 mutations (Figure 2).
Molecular subsets of gliomas and medulloblastomas
Genotyping is beginning to influence treatment decisions
(Figure 1). The case for molecular diagnosis as a guide to ther-
apy is especially robust for oligodendroglioma (Cairncross et
al., 1998; Ino et al., 2001; Smith et al., 2000). Approximately
60% of anaplastic oligodendrogliomas respond to a chemother-
apy regimen called PCV (procarbazine, CCNU, and vincristine)
(Cairncross et al., 1994). Those patients whose tumors have 1p
loss essentially always respond to PCV, and those with com-
bined 1p and 19q loss that lack other detectable alterations
have durable responses and long survival times (over 10 years).
In contrast, those whose tumors lack these genetic alterations
but harbor others such as EGFR amplification rarely respond to
PCV in a durable manner and have short survivals (less than 2
years). Hence, genotyping can direct the former group (1p loss)
to initial PCV instead of radiotherapy, which is sometimes neu-
rotoxic; the latter group (1p intact) can forego the unpleasant-
ness and myelosuppression of PCV in favor of radiotherapy,
which causes few side effects in patients with short survival
times. It remains to be shown if 1p and 19q loss will also predict
response to temozolomide, a new chemotherapeutic agent with
antiglioma activity and a more favorable side-effect profile than
PCV (Yung et al., 1999).
Glioblastomas can be divided into
those with TP53 mutations and those with EGFR amplification,
events which appear mutually exclusive (Figure 1; Kleihues and
Cavenee, 2000). Patients whose glioblastomas have TP53
mutations are often so-called secondary glioblastomas, in
which glioblastoma has arisen in a prior lower grade astrocy-
toma, typically in younger adult patients. TP53 mutations are
also common in glioblastomas having many giant cells. EGFR
gene amplification, on the other hand, typically occurs in so-
called primary (or “de novo”) glioblastomas, which appear to
arise quite suddenly in older adult patients, as well as in small
cell glioblastomas (Burger et al., 2001).Those high-grade astro-
cytic tumors with EGFR amplification and/or overrepresentation
of chromosome 7 may follow more aggressive clinical courses
and be less responsive to radiotherapy than glioblastomas with
TP53 mutations, but such differences do not yet influence clini-
cal management (Barker et al., 2001; Kunwar et al., 2001; Smith
et al., 2001). Moreover, it has not yet been possible to identify a
molecular marker for the rare high-grade astrocytic gliomas that
are cured by existing brain tumor therapies.
In the past decade, several developmentally regulated
genes have been identified as markers that are associated with
medulloblastoma outcome (Figure 2). Expression of the neu-
rotrophin-3 receptor, TrkC, is associated with favorable clinical
outcome (Segal et al., 1994). Increased expression of the
neuregulin receptors erbB2 and erbB4 and of c-myc, however,
are highly correlated with poor outcome (Gilbertson et al., 1997;
Herms et al., 2000). Gene expression profiling with DNA
oligonucleotide microarrays predicts favorable outcome for
tumors expressing genes characteristic of cerebellar differentia-
tion or encoding extracellular matrix proteins. In contrast, poor
outcome is associated with expression of genes related to cell
proliferation, multidrug resistance, and ribosomal biogenesis
(Pomeroy et al., 2002). Expression profiles associated with
metastasis include platelet-derived growth factor receptor α
(PDGFRA) and genes in the ras/MAPK signaling pathway
(MacDonald et al., 2001)
Animal models
A major recent advance in neurooncology has been the ability
Figure 1. Traditional and molecular approaches
to malignant glioma classification 
Traditional histopathology classifies diffuse
gliomas as astrocytomas, oligodendrogliomas,
or oligoastrocytomas and assigns grades with
anaplastic oligodendrogliomas and glioblas-
tomas representing the high-grade lesions. Since
particular genetic events (red italics) are associ-
ated with tumor histology, such as TP53 muta-
tions in astrocytic tumors and 1p/19q loss in
oligodendrogliomas, it is likely that genotyping
will eventually classify tumors (bold red arrows).
For instance, so-called oligoastrocytomas will be
classified as either astrocytoma or oligoden-
droglioma. In addition, anaplastic oligoden-
drogliomas will be defined by a certain geno-
type, and other histologically similar tumors
could be grouped with the glioblastomas. A
combined histological-genetic approach would
divide the tumors into clinically relevant groups
with respect to survival and response to therapy
(blue boxes). Abbreviations: TP53 mut, TP53
mutation; EGFR amp, EGFR amplification; 1p−
/19q−, allelic losses of 1p and 19q; prognosis val-
ues are estimates of median survival; tx, treat-
ment.
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to model glioma and medulloblastoma in mice using transgenic
technologies (Holland, 2001; Wechsler-Reya and Scott, 2001).
Such models now, for the first time, faithfully replicate the cardi-
nal histological features of glioma—particularly glioblastoma—
including white and gray matter invasion, vascular proliferation,
and necrosis with tumor cell palisades. Such glioma models
could be valuable for understanding the pathways responsible
for glial tumorigenesis and for identifying novel therapeutic tar-
gets and also hold future promise for preclinical testing of novel
therapies, especially when the transgenic alterations mimic
those pathways deregulated in human gliomas (Holland, 2001).
Mice with targeted mutation of the murine homolog of PTCH
develop medulloblastomas, again offering a powerful tool for
investigating dysregulated genetic pathways important in
human medulloblastoma and potentially for preclinical trials
(Wechsler-Reya and Scott, 2001).
New targets and novel therapies
The identification of molecular signatures that guide the use of
existing therapies for individual patients—maximizing benefit
and minimizing toxicity—is an important development in neu-
rooncology, but the emergence of safe, curative treatments will
require a deeper understanding of glioma and medulloblastoma
biology.With such knowledge will come rationally designed, effi-
cacious brain tumor therapies, analogous to STI571, the syn-
thetic kinase inhibitor that reverses chronic myelogenous
leukemia (CML) (Maura et al., 2002).
Broadly speaking, new therapies for CNS tumors can be
anticipated in three arenas: (1) signal transduction blockade, (2)
cell cycle control restoration, or (3) “effector” molecule inhibi-
tion. Activation of EGFR, PDGF, and ras signaling in high-grade
astrocytomas suggests utility for inhibitors of receptor protein
tyrosine kinases, farnesyltransferases, or protein kinase C path-
ways; such drugs are currently being evaluated in phase I/II
malignant glioma trials. The association of poor medulloblas-
toma outcome with PDGFRA, ras/MAP kinase signaling, and
ribosomal protein expression also provides a rational basis for
signal transduction inhibitors in medulloblastoma treatment.
Moreover, specific and potent blockers of
Shh signaling have been identified and
are being developed for clinical use,
which could be of particular value for
desmoplastic medulloblastomas (Taipale
et al., 2000).
Inactivation of the p16 and p53 path-
ways argues that loss of cell cycle control
contributes to gliomagenesis. Virally
mediated gene transfer of functional p16,
Rb, or p53, and mTOR inhibition with
rapamycin analogs to restore the G1/S checkpoint are other
examples of glioma therapies under development. Glioma cells
synthesize matrix-degrading metalloproteinases and angio-
genic molecules such as vascular endothelial growth factor
(VEGF). These effector molecules contribute to invasion and
vascular proliferation, cardinal features of malignant glioma
histopathology. Reversing these behaviors with targeted
inhibitors, some of which are now under study, may have thera-
peutic benefits. Oncolytic viruses—to deliver “chemosensitiz-
ing” genes and to lyse proliferating cells (e.g., attenuated her-
pes viruses)—have also entered clinical testing. Nonetheless,
the tendency for human gliomas to invade widely and for medul-
loblastomas to metastasize could be significant obstacles to the
effective delivery of such oncolytic viruses.
Future challenges
Advances in developmental neurobiology will no doubt augment
our understanding of brain tumorigenesis, and there is a need
for integration of developmental neurobiology with neuro-oncol-
ogy (Louis et al., 2000). Indeed, from a therapeutic perspective,
it may be especially important to understand early events. If
STI571 for CML is any guide, new brain tumor therapies may be
most effective when administered at an earlier stage in the neo-
plastic process, thus targeting critical tumor maintenance
mechanisms (Maura et al., 2002). This, however, raises the
thorny problem of early detection of brain tumors, with its tech-
nical and social challenges. In addition, a better understanding
of the unique immunological environment of the CNS and of the
biology of the blood-brain barrier will be important to the devel-
opment and delivery of effective new therapies for glioma and
medulloblastoma (Louis et al., 2000). Last, but certainly not
least, improvement in the quality of life of patients suffering with
CNS neoplasms is a goal of the highest priority.
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